Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 5Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × gedatolisib × Clear all
NCT03911973 2024-06-07

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
37 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03243331 2021-01-07

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Indiana University

Phase 1 Completed
18 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡